文献速递细菌感染、耐药与抗菌药物医院感染防控

抗菌药物短缺及应对策略的系统综述

A systematic review of antibiotic drug shortages and the strategies employed for managing these shortages.
PubMed 文献 · Clin Microbiol Infect · 2024-09-26

该系统综述检索了PubMed/MEDLINE、EMBASE、Scopus和Web of Science,纳入2000年1月至2023年7月发表的英文研究,最终分析74项研究(82.4%来自高收入国家)。短缺最常见于哌拉西林-他唑巴坦(28.4%),多数短缺抗菌药物属WHO Watch类别(51%)。短缺的临床影响包括住院时间延长、使用劣质替代药物后治疗失败及对抗菌药物管理项目的负面影响;成功缓解策略主要由抗菌药物管理和感染病团队驱动。

要点

  • 短缺最常见于哌拉西林-他唑巴坦(21/74,28.4%),多数短缺药物属WHO Watch类别(27/54,51%)。
  • 短缺常见原因为生产中断,如活性药物成分和原材料供应问题。
  • 临床影响包括住院时间延长、使用劣质替代药物后治疗失败及对抗菌药物管理项目的负面影响。

核心结论

  • 抗菌药物短缺直接或间接由经济可行性和对单一来源原料的依赖驱动。
  • 有限的临床结局数据显示影响不一,部分感染变得更难治疗,但尚无可靠数据说明短缺对耐药性的影响。
  • 管理短缺的缓解策略严重依赖抗菌药物管理团队。

研究设计与样本

  • 系统综述,检索PubMed/MEDLINE、EMBASE、Scopus和Web of Science,纳入2000年1月至2023年7月发表的英文研究。
  • 最终分析纳入74项研究,其中61/74(82.4%)来自高收入国家。
  • 使用Joanna Briggs研究所针对各研究设计最合适的工具评估方法学质量,数据采用描述性统计进行定性和定量合成。

主要发现

  • 短缺最常见于哌拉西林-他唑巴坦(21/74,28.4%),多数报告的短缺抗菌药物属WHO Watch类别(27/54,51%)。
  • 短缺的常见原因为生产中断,如活性药物成分和原材料供应问题。
  • 临床影响包括住院时间延长、使用劣质替代药物后治疗失败及对抗菌药物管理项目的负面影响。
  • 尚无可靠的短缺经济影响分析。
  • 成功报告的缓解策略由医院抗菌药物管理和感染病团队驱动。

关键数值与推荐

  • 纳入标准为2000年1月至2023年7月发表的英文研究,涉及管理应对短缺的医疗、政策和策略团队及受短缺影响的患者人群。

临床怎么用

  • 成功报告的缓解策略由医院抗菌药物管理和感染病团队驱动。

局限性

  • 尚无可靠的短缺经济影响分析。
  • 有限的临床结局数据显示影响不一,尚无可靠数据说明短缺对耐药性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a need to examine the impact of increasingly prevalent antibiotic shortages on patient outcomes and on the emergence and spread of antimicrobial resistance. OBJECTIVES: To: (1) assess patterns and causes of shortages; (2) investigate the effect of shortages on health systems and patient outcomes; and (3) identify strategies for forecasting and managing shortages. DATA SOURCES: PubMed/MEDLINE, EMBASE, Scopus, and Web of Science. STUDY ELIGIBILITY CRITERIA: Studies published in English from January 2000 to July 2023. Participants health care, policy, and strategic teams managing and responding to shortages. Patient populations (adults and children) affected by shortages. PARTICIPANTS: Healthcare workers responding to and populations affected by antibiotic shortages. INTERVENTIONS: Strategies, policies, and mitigation options for managing and responding to antibiotic drug shortages. ASSESSMENT OF RISK OF BIAS: The methodological quality of included studies was reviewed using the most appropriate tool from Joanna Briggs institute critical appraisal tool for each study design. METHODS OF DATA SYNTHESIS: Data synthesis was qualitative and quantitative using descriptive statistics. RESULTS: The final analysis included 74 studies (61/74, 82.4% high-income countries). Shortages were most reported for piperacillin-tazobactam (21/74, 28.4%), with most of the reported antibiotics being in the WHO Watch category (27/54, 51%). Frequent cause of shortages was disruption in manufacturing, such as supply of active pharmaceutical ingredients and raw materials. Clinical implications of shortages included increased length of hospital stay, treatment failure after using inferior alternative agents, and a negative impact on antimicrobial stewardship programmes (AMS). Robust economic impact analysis of shortages is unavailable. Successfully reported mitigation strategies were driven by AMS and infectious diseases teams in hospitals. CONCLUSIONS: Antibiotic shortages are directly or indirectly driven by economic viability and reliance on single source ingredients. The limited data on clinical outcomes indicates a mixed effect, with some infections becoming more difficult to treat, though there is no robust data on the impact of shortages on antimicrobial resistance. The mitigation strategies to manage shortages rely heavily on AMS teams.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Pandey AK, Cohn J, Nampoothiri V, et al. A systematic review of antibiotic drug shortages and the strategies employed for managing these shortages. Clin Microbiol Infect. 2024. PMID: 39341418. doi:10.1016/j.cmi.2024.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。